Ardelyx (ARDX) Expected to Announce Quarterly Earnings on Thursday

Ardelyx (NASDAQ:ARDX - Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Thursday, February 20th. Analysts expect the company to announce earnings of $0.02 per share and revenue of $111.16 million for the quarter. Parties interested in listening to the company's conference call can do so using this link.

Ardelyx Trading Up 2.3 %

Shares of ARDX traded up $0.13 during trading hours on Friday, hitting $5.79. The company had a trading volume of 3,514,262 shares, compared to its average volume of 4,426,183. The firm has a market cap of $1.37 billion, a P/E ratio of -19.30 and a beta of 0.85. The stock's 50 day moving average price is $5.24 and its 200 day moving average price is $5.63. The company has a quick ratio of 3.87, a current ratio of 4.03 and a debt-to-equity ratio of 0.64. Ardelyx has a 52-week low of $4.32 and a 52-week high of $9.83.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Jefferies Financial Group reduced their price target on Ardelyx from $11.00 to $8.00 and set a "buy" rating on the stock in a report on Thursday, January 2nd. HC Wainwright restated a "neutral" rating and set a $5.50 price target on shares of Ardelyx in a report on Thursday, January 16th. Piper Sandler boosted their price target on Ardelyx from $7.00 to $8.00 and gave the company a "neutral" rating in a report on Monday, January 27th. Citigroup reduced their target price on Ardelyx from $12.00 to $10.00 and set a "buy" rating on the stock in a report on Monday, November 4th. Finally, Cantor Fitzgerald upgraded Ardelyx to a "strong-buy" rating in a report on Thursday, January 30th. Three equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $9.42.

Insider Transactions at Ardelyx

In related news, CEO Michael Raab sold 41,666 shares of the company's stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $5.36, for a total value of $223,329.76. Following the transaction, the chief executive officer now directly owns 1,108,719 shares of the company's stock, valued at approximately $5,942,733.84. This represents a 3.62 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director David M. Mott acquired 213,300 shares of the stock in a transaction that occurred on Thursday, December 19th. The stock was acquired at an average cost of $4.67 per share, for a total transaction of $996,111.00. Following the completion of the transaction, the director now directly owns 1,638,765 shares in the company, valued at $7,653,032.55. This represents a 14.96 % increase in their position. The disclosure for this purchase can be found here. Insiders have sold a total of 177,938 shares of company stock valued at $924,239 in the last ninety days. 5.90% of the stock is currently owned by corporate insiders.

Ardelyx Company Profile

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.